Nanobiotix (NBTX) has released an update.
Nanobiotix has revealed promising early results for its novel treatment approach, NBTXR3, when used in combination with anti-PD-1 therapy for patients with advanced head and neck cancer, including those who have not responded to previous treatments. The data, presented at ASCO 2024, indicates that the treatment is well-tolerated and shows signs of efficacy in controlling disease and shrinking tumors, which supports further investigation in randomized clinical trials. The company plans to discuss these findings in an upcoming investor event and continue research on NBTXR3’s broad potential across various solid tumors.
For further insights into NBTX stock, check out TipRanks’ Stock Analysis page.
